Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25.

Slides:

Advertisements

Similar presentations

Things we knew, things we did… Things we have learnt, things we should do LIPID MANAGEMENT IN PRIMARY CARE: HOW WELL DO WE DO? Dr. Carlos Brotons Research.

Advertisements

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Newly diagnosed hypertensive patients with type 2 diabetes (n = 1544) Randomisation Avoid ACE inhibitors/ beta-blockers (n = 390) Tight BP control (n =

P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Insights from clinical trials: The unassailable case for LDL-c.

The efFects of Pharmacological management of lipids in patients with CKD Andrew Monson FY1 18/9/14.

On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs. 2004;9: LaRosa JC et al. N Engl J Med. 2005;352:

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.

The Indian Polycap Study (TIPS). Lancet 2009 Mar 30 [Epub]

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:

SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

Amarenco P, Labreuche J. Lancet Neurol 2009;8:

4S: Scandinavian Simvastatin Survival Study

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet 2010;epub 9 Nov.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:

Baseline characteristics of HPS participants by prior cerebrovascular disease.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials Lancet 2010;

Volume 376, Issue 9753, Pages (November 2010)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

LDL cholesterol in CKD—to treat or not to treat?

All-cause mortality by treatment group

Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular.

2013 ACC/AHA cholesterol treatment guidelines

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.

Cholesterol Lowering and CV Risk: Meta-analyses

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

Pravastatin in Elderly Individuals at Risk of Vascular Disease

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.

ELIGIBILITY: MRC/BHF Heart Protection Study

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

Volume 388, Issue 10059, Pages (November 2016)

HDL cholesterol and cardiovascular risk Epidemiological evidence

HDL cholesterol and cardiovascular risk

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Improving outcomes for CVD

Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

Baseline characteristics of HPS participants by prior diabetes

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

2013 ACC/AHA cholesterol treatment guidelines

Volume 375, Issue 9725, Pages (May 2010)

MRC/BHF Heart Protection Study

Volume 376, Issue 9753, Pages (November 2010)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

LDL cholesterol in CKD—to treat or not to treat?

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection.

Heart Protection Study Collaborative Group Lancet 2011;377:469-76

Estimated 5-year rate of a first major vascular event (MVE), major coronary event (MCE),or vascular death in univariate and multivariate risk subgroups.

Cause of death Treatment-arm events, % (n=45 054)

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

PROSPER: trial design

Flow of study participants

LDL-c reductions below 1

Presentation transcript:

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

Baseline characteristics of participants presenting with or without diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

Proportional effects on cause-specific mortality per mmol/L reduction in LDL cholesterol in participants presenting with or without diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol in participants presenting with or without diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol in participants with and without diabetes by history of vascular disease Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol by baseline prognostic factors in participants with diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol by baseline lipid profi le in participants with diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol, by year, in participants with and without diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25